Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.00.

Separately, Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th.

Institutional Investors Weigh In On Evaxion A/S

Several hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Evaxion A/S in the fourth quarter worth about $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S in the fourth quarter valued at approximately $48,000. SmartHarvest Portfolios LLC purchased a new stake in Evaxion A/S in the 4th quarter worth approximately $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Evaxion A/S during the 1st quarter worth approximately $112,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S in the 1st quarter valued at $146,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion A/S Price Performance

Shares of EVAX opened at $3.15 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The company’s fifty day moving average price is $3.13 and its 200-day moving average price is $3.56. Evaxion A/S has a 1-year low of $2.52 and a 1-year high of $12.15. The firm has a market capitalization of $26.27 million, a PE ratio of -2.60 and a beta of 0.29.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.